Clinical Trial

Cardiac Stunning After Electrical Cardioversion

Study acronym: AMPEA
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 31, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to evaluate cardiac stunning and electrocardiographic parameters through transthoracic echocardiography and 24 hours ECG conducted immediately following electrical cardioversion. The main question it aims to answer is: Do echocardiographic and electrocardiographic parameters relating to cardiac stunning predict atrial fibrillation (AF) recurrence rates after electrical cardioversion? Participants will undergo echocardiography and a 24-hour Holter monitoring immediately after electrical cardioversion.
Trial Details
NCT Number NCT06752733
Lead Sponsor Korea University Guro Hospital
Conditions Atrial Fibrillation (AF)
Enrollment 160 participants
Start Date 2024-02-20
Primary Completion 2025-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-31